U.S. Patent No. 12,257,071 (‘071 patent) relates to advanced catheter-based systems that combine nerve mapping and radiofrequency (RF) ablation. The technologies provide enhanced precision in treating nerve-related conditions.

The Woodlands, Texas-based Autonomix said its systems enable the identification and ablation of overactive nerves within the peripheral nervous system using a minimally invasive approach. Its new patent marks a step forward in the company’s mission, according to a news release. It wants to deliver more effective, less invasive treatments for neurological conditions like chronic pain, hypertension and more.

Autonomix said its patent covers features of the technology such as deployable microfingers with embedded sensors for real-time monitoring. It also extends to the ability to map, stimulate, ablate and assess nerve activity in a single integrated system. Additionally, the patent covers feedback-driven control for multiple types of procedures and supports adaptive modulation.